355 related articles for article (PubMed ID: 17548753)
1. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
[TBL] [Abstract][Full Text] [Related]
2. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
[TBL] [Abstract][Full Text] [Related]
3. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
4. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
5. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
7. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease.
Ewers M; Cheng X; Zhong Z; Nural HF; Walsh C; Meindl T; Teipel SJ; Buerger K; He P; Shen Y; Hampel H
J Alzheimers Dis; 2011; 25(2):373-81. PubMed ID: 21460439
[TBL] [Abstract][Full Text] [Related]
8. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
10. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
11. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
12. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains.
Harada H; Tamaoka A; Ishii K; Shoji S; Kametaka S; Kametani F; Saito Y; Murayama S
Neurosci Res; 2006 Jan; 54(1):24-9. PubMed ID: 16290302
[TBL] [Abstract][Full Text] [Related]
13. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
15. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
Fellgiebel A; Kojro E; Müller MJ; Scheurich A; Schmidt LG; Fahrenholz F
J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
[TBL] [Abstract][Full Text] [Related]
16. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
18. Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression.
Post A; Ackl N; Rücker M; Schreiber Y; Binder EB; Ising M; Sonntag A; Holsboer F; Almeida OF
Biol Psychiatry; 2006 May; 59(9):858-62. PubMed ID: 16325150
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
20. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Mattsson N; Axelsson M; Haghighi S; Malmeström C; Wu G; Anckarsäter R; Sankaranarayanan S; Andreasson U; Fredrikson S; Gundersen A; Johnsen L; Fladby T; Tarkowski A; Trysberg E; Wallin A; Anckarsäter H; Lycke J; Andersen O; Simon AJ; Blennow K; Zetterberg H
Mult Scler; 2009 Apr; 15(4):448-54. PubMed ID: 19153172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]